Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer by Bakir Mehić, Mirko Stanetić, Ljuljeta Tinjić, Vlatka Smoljanović

Get full text

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatm... by Johannes Noé, PhD, Walter Bordogna, PhD, Venice Archer, MD, Vlatka Smoljanovic, MD, Magalie Hilton, MSc, Ryan Woodhouse, BSc, Simonetta Mocci, MD, PhD, Shirish M. Gadgeel, MD

Get full text

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastas... by Qing Zhang, PhD, Jessica J. Lin, MD, Navdeep Pal, M.B.B.S., MPH, Letizia Polito, PhD, Huong Trinh, MD, Magalie Hilton, MSc, Vlatka Smoljanović, MD, Nino Kurtsikidze, MD, Venice Archer, MD, Matthew G. Krebs, MD, PhD

Get full text